Federal Drug Researchers Facing Conflict Probe ; 2 Accepted Fees in Private Deals

Summary

---

WASHINGTON A senior researcher at the National Institutes of Health engaged in "serious misconduct" by entering into dozens of unauthorized private arrangements with drug companies and failing to report annually the outside income, totaling more than $100,000, a confidential internal review by the agency has found.

Officials at the NIH concluded late last year that the actions of Dr. Thomas J. Walsh, who has helped lead major clinical trials involving cancer patients, might result in dismissal from federal government service. No disciplinary action has been taken.

See the full content of this document

Extract

---

Federal Drug Researchers Facing Conflict Probe ; 2 Accepted Fees in Private Deals

The internal review, conducted by lawyers and other ethics specialists within the office of the NIH director, found that from 1999 to 2004, Walsh received fees totaling $100,970 from pharmaceutical and biotechnology companies. He accepted fees from 25 companies and has led government-sponsored researc...

See the full content of this document

---